60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
60 Degrees Pharmicals收到美國食品藥品管理局對他非諾喹-巴貝斯蟲病臨床試驗方案的評論；無需進行實質性更改，試驗計劃和執行按計劃進行
60 Degrees Pharmaceuticals Receives FDA Comments On Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required, Trial Planning And Execution To Proceed As Planned
60 Degrees Pharmicals收到美國食品藥品管理局對他非諾喹-巴貝斯蟲病臨床試驗方案的評論；無需進行實質性更改，試驗計劃和執行按計劃進行
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。